Innovent BiologicsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Innovent Biologics (1801.HK) reported revenue of $971.00M in Q4 2025.
H2 2016-H2 2025(All available data)
H1 2016-H2 2025
Innovent BiologicsChina-based biopharma. Mazdutide (dual GCG/GLP-1) approved by China NMPA June 2025 for chronic weight management; first dual GCG/GLP-1 agonist globally. Partnership with Eli Lilly.
Innovent Biologics (1801.HK) is a Biotechnology company. China-based biopharma. Mazdutide (dual GCG/GLP-1) approved by China NMPA June 2025 for chronic weight management; first dual GCG/GLP-1 agonist globally. Partnership with Eli Lilly. It was founded in 2011, is headquartered in Suzhou, China and employs about 5,000 people.
Track Innovent Biologics's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 23, 2026.
Sterling groups Innovent Biologics in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Innovent Biologics, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.